Lupin Limited has informed the Exchange regarding a press release dated May 19, 2026, titled "Lupin Makes its Debut in Dow Jones Best-in-Class Indices 2026".
Press Release May 19 2026
Filed with NSE ·
6ix hasn’t read this filing yet.
Earlier from Lupin
- Lupin Receives Tentative Approval from U.S. FDA for Revefenacin Inhalation Solution
- Press Release May 18 2026
- Press Release May 15 2026
- Lupin Receives U.S. FDA Approval for Famotidine Injection, USP
- Press Release May 13 2026
Later from Lupin
- Press Release May 22 2026
- Lupin Receives China Approval for Oseltamivir Phosphate Oral Suspension
- Press Release May 28 2026
- Lupin Shares Phase 1 Data on LNP8701 at the ASCO Annual Meeting 2026
- Press Release May 29 2026
Follow Lupin into a list and get an email when it puts out news.
Follow Lupin